Once-weekly dalbavancin versus daily conventional therapy for skin infection

New England Journal of Medicine

Volumn 370, Issue 23, 2014, Pages 2169-2179

  Boucher, Helen W ^a   Wilcox, Mark ^b   Talbot, George H ^c   Puttagunta, Sailaja ^d   Das, Anita F ^e   Dunne, Michael W ^d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Talbot Advisors   (United States)

^d Durata Therapeutics   (United States)

^e InClin ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; LINEZOLID; VANCOMYCIN;

ABSCESS; ACUTE KIDNEY FAILURE; ADULT; AGED; ANAPHYLAXIS; ARTICLE; BACTERIAL SKIN DISEASE; CELLULITIS; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNSPECIFIED SIDE EFFECT; WOUND INFECTION;

ACETAMIDES; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; TEICOPLANIN; VANCOMYCIN; YOUNG ADULT;

EID: 84901794881     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1310480     Document Type: Article

References (16)

1. Jenkins TC, Knepper BC, Sabel AL, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med 2011;171:1072-9.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-e55. [Erratum, Clin Infect Dis 2011;53:319.]
3. Daum RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007;357:380-90. [Erratum, N Engl J Med 2007;357:1357.]
4. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis 2010;51:895-903.
5. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:1407-15.
6. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005;55:Suppl 2:ii25-ii30. (Pubitemid 40425476)
7. Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother 2006;58:627-31. (Pubitemid 44288129)
8. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40:374-80. (Pubitemid 40216504)
9. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003;37:1298-303. (Pubitemid 37433624)
10. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Silver Spring, MD: Food and Drug Administration, 2010.
11. Snodgrass WR, Anderson T. Sulphanilamide in the treatment of erysipelas. Br Med J 1937;2:1156-9.
12. Idem. Prontosil in erysipelas. Br Med J 1937;2:101-4.
13. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7. [Erratum, Clin Infect Dis 2009;49:1465.]
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-26. (Pubitemid 15055349)
15. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65:Suppl 4:iv41-iv51.
16. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309:559-69.